Evidence map›Paper›PMID 31079238›Full record

ReviewExperimental brain research2019

In vivo electrophysiological recordings of the effects of antidepressant drugs.

Paul J Fitzgerald, Brendon O Watson

Open access · hybridAbstract readReview
In one paragraph

Review in Experimental brain research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Ketamine and the Future of Rapid-Acting Antidepressants.Annual review of clinical psychology · 2021
    Review
  14. Article
  15. Are Noradrenergic Transmission Reducing Drugs Antidepressants?Frontiers in behavioral neuroscience · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Acute 5-HTFrontiers in pharmacology · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Paul J FitzgeraldDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, 48109-5720, USA. pafitzge@umich.edu.
Brendon O WatsonDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, 48109-5720, USA. brendonw@umich.edu.ORCID http://orcid.org/0000-0002-9940-4579
University of Michigan · US

Funding

National Institutes of Health K08 MH107662
6 · The paper itself

Abstract

Antidepressant drugs are a standard biological treatment for various neuropsychiatric disorders, yet relatively little is known about their electrophysiologic and synaptic effects on mood systems that set moment-to-moment emotional tone. In vivo electrical recording of local field potentials (LFPs) and single neuron spiking has been crucial for elucidating important details of neural processing and control in many other systems, and yet electrical approaches have not been broadly applied to the actions of antidepressants on mood-related circuits. Here we review the literature encompassing electrophysiologic effects of antidepressants in animals, including studies that examine older drugs, and extending to more recently synthesized novel compounds, as well as rapidly acting antidepressants. The existing studies on neuromodulator-based drugs have focused on recording in the brainstem nuclei, with much less known about their effects on prefrontal or sensory cortex. Studies on neuromodulatory drugs have moreover focused on single unit firing patterns with less emphasis on LFPs, whereas the rapidly acting antidepressant literature shows the opposite trend. In a synthesis of this information, we hypothesize that all classes of antidepressants could have common final effects on limbic circuitry. Whereas NMDA receptor blockade may induce a high powered gamma oscillatory state via direct and fast alteration of glutamatergic systems in mood-related circuits, neuromodulatory antidepressants may induce similar effects over slower timescales, corresponding with the timecourse of response in patients, while resetting synaptic excitatory versus inhibitory signaling to a normal level. Thus, gamma signaling may provide a biomarker (or "neural readout") of the therapeutic effects of all classes of antidepressants.

Indexed as

Action PotentialsAnimalsAntidepressive AgentsDepressionElectrophysiological PhenomenaExcitatory Amino Acid AntagonistsGamma RhythmHumansPrefrontal CortexReceptors, N-Methyl-D-AspartateAntidepressive AgentsExcitatory Amino Acid AntagonistsReceptors, N-Methyl-D-AspartateGamma oscillationsKetamineMAOiSNRISSRITricyclic

Identifiers

PMID31079238
PMCPMC6584243
OpenAlexW2944312626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.